Advertisement

Tumor Biology

, Volume 35, Issue 12, pp 12339–12344 | Cite as

MiR-25 promotes ovarian cancer proliferation and motility by targeting LATS2

  • Shujun Feng
  • Wenjing Pan
  • Ye Jin
  • Jianhua ZhengEmail author
Research Article

Abstract

Ovarian cancer (OC) is a major cancer-related mortality among women. Recent studies suggest that many microRNAs (miRNAs) were dysregulated and involved in tumorigenesis of OC. The present study investigated the role of miR-25 in the development and progression of OC. The expression of miR-25 was increased in OC tissues and cell lines. Inhibition of miR-25 remarkably suppressed proliferation, migration, and invasion of OC cells. Large tumor suppressor 2 (LATS2), a tumor suppressor, was confirmed to be a direct target of miR-25 in OC cells. Moreover, restoration of LATS2 significantly attenuated the oncogenic effects of miR-25. Together, our data suggest an oncogenic role of miR-25 in OC and a potentially novel diagnostic and therapeutic target for OC treatment.

Keywords

Ovarian cancer MiR-25 Proliferation Migration Invasion 

Notes

Conflicts of interest

None

References

  1. 1.
    Kim K, Zang R, Choi SC, Ryu SY, Kim JW. Current status of gynecological cancer in China. J Gynecol Oncol. 2009;20:72–6.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Suh DH, Kim JW, Kim K, Kim HJ, Lee KH. Major clinical research advances in gynecologic cancer in 2012. J Gynecol Oncol. 2013;24:66–82.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.PubMedCrossRefGoogle Scholar
  4. 4.
    Parikh A, Lee C, Peronne J, Marchini S, Baccarini A, Kolev V, et al. MicroRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun. 2014;5:2977.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Kentwell J, Gundara JS, Sidhu SB: Noncoding RNAs in endocrine malignancy. The oncologist 2014Google Scholar
  6. 6.
    Alsaleh G, Gottenberg JE. Characterization of microRNAs and their targets. Methods Mol Biol. 2014;1142:55–63.PubMedCrossRefGoogle Scholar
  7. 7.
    Li W, Liu Z, Chen L, Zhou L, Yao Y: MicroRNA-23b is an independent prognostic marker and suppresses ovarian cancer progression by targeting runt-related transcription factor-2. FEBS letters. 2014;588(9):1608–15.Google Scholar
  8. 8.
    Xia J, Guo X, Yan J, Deng K: The role of mir-148a in gastric cancer. Journal of cancer research and clinical oncology. J Cancer Res Clin Oncol. 2014;140(9):1451–56.Google Scholar
  9. 9.
    Li S, Li Y, Wen Z, Kong F, Guan X, Liu W. microRNA-206 overexpression inhibits cellular proliferation and invasion of estrogen receptor alphapositive ovarian cancer cells. Mol Med Rep. 2014;9:1703–8.PubMedGoogle Scholar
  10. 10.
    Shen W, Song M, Liu J, Qiu G, Li T, Hu Y, et al. Mir-26a promotes ovarian cancer proliferation and tumorigenesis. PLoS One. 2014;9:e86871.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Wang X, Meng X, Li H, Liu W, Shen S, Gao Z: MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer. Clin Translational Oncol: Off Publ Federat Spanish Oncol Soc Natl Cancer Institute Mexico. Biochem Biophys Res Commun. doi: 10.1007/s12094-014-1178-6.
  12. 12.
    Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, et al. Tumour angiogenesis regulation by the mir-200 family. Nat Commun. 2013;4:2427.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Wang S, Zhao X, Wang J, Wen Y, Zhang L, Wang D, et al. Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer. Med Oncol. 2013;30:681.PubMedCrossRefGoogle Scholar
  14. 14.
    Xu FX, Su YL, Zhang H, Kong JY, Yu H, Qian BY. Prognostic implications for high expression of mir-25 in lung adenocarcinomas of female non-smokers. Asian Pacific J Cancer Prev: APJCP. 2014;15:1197–203.CrossRefGoogle Scholar
  15. 15.
    Zhao H, Wang Y, Yang L, Jiang R, Li W. Mir-25 promotes gastric cancer cells growth and motility by targeting RECK. Mol Cell Biochem. 2014;385:207–13.PubMedCrossRefGoogle Scholar
  16. 16.
    Xu X, Chen Z, Zhao X, Wang J, Ding D, Wang Z, et al. MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma. Biochem Biophys Res Commun. 2012;421:640–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Zhang H, Zuo Z, Lu X, Wang L, Wang H, Zhu Z. Mir-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol Rep. 2012;27:594–8.PubMedGoogle Scholar
  18. 18.
    Yabuta N, Fujii T, Copeland NG, Gilbert DJ, Jenkins NA, Nishiguchi H, et al. Structure, expression, and chromosome mapping of LATS2, a mammalian homologue of the drosophila tumor suppressor gene lats/warts. Genomics. 2000;63:263–70.PubMedCrossRefGoogle Scholar
  19. 19.
    Yu T, Bachman J, Lai ZC. Evidence for a tumor suppressor role for the large tumor suppressor genes LATS1 and LATS2 in human cancer. Genetics. 2013;195:1193–6.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Adler JJ, Johnson DE, Heller BL, Bringman LR, Ranahan WP, Conwell MD, et al. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of angiomotin by the LATS1/2 protein kinases. Proc Natl Acad Sci U S A. 2013;110:17368–73.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Dai X, She P, Chi F, Feng Y, Liu H, Jin D, et al. Phosphorylation of angiomotin by LATS1/2 kinases inhibits f-actin binding, cell migration, and angiogenesis. J Biol Chem. 2013;288:34041–51.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Visser S, Yang X. LATS tumor suppressor: a new governor of cellular homeostasis. Cell Cycle. 2010;9:3892–903.PubMedCrossRefGoogle Scholar
  23. 23.
    Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, et al. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res: Off J Am Assoc Cancer Res. 2005;11:1380–5.CrossRefGoogle Scholar
  24. 24.
    Fang L, Du WW, Yang W, Rutnam ZJ, Peng C, Li H, et al. Mir-93 enhances angiogenesis and metastasis by targeting LATS2. Cell Cycle. 2012;11:4352–65.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Yang X, Yu J, Yin J, Xiang Q, Tang H, Lei X. Mir-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2. Die Pharmazie. 2012;67:645–51.PubMedGoogle Scholar
  26. 26.
    Xia Y, Gao Y: MicroRNA-181b promotes ovarian cancer cell growth and invasion by targeting LATS2. Biochem Biophys Res Commun. 2014;447(3):446--51.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Shujun Feng
    • 1
  • Wenjing Pan
    • 1
  • Ye Jin
    • 1
  • Jianhua Zheng
    • 1
    Email author
  1. 1.Department of Obstetrics and GynecologyThe Second Affiliated Hospital of Harbin Medical UniversityHarbinChina

Personalised recommendations